These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 26226307)

  • 1. Insights on the immunogenicity of antibody-drug conjugates.
    Carrasco-Triguero M
    Bioanalysis; 2015; 7(13):1565-8. PubMed ID: 26226307
    [No Abstract]   [Full Text] [Related]  

  • 2. An integrated multiplatform bioanalytical strategy for antibody-drug conjugates: a novel case study.
    Myler H; Rangan VS; Wang J; Kozhich A; Cummings JA; Neely R; Dail D; Liu A; Wang B; Vezina HE; Freebern W; Sung MC; Passmore D; Deshpande S; Kempe T; Gu H; Saewert M; Manney A; Lute J; Zambito F; Wong RL; Piccoli SP; Aubry AF; Pillutla R; Arnold M; DeSilva B
    Bioanalysis; 2015; 7(13):1569-82. PubMed ID: 26226308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges in antibody-drug conjugate discovery: a bioconjugation and analytical perspective.
    Rao C; Rangan VS; Deshpande S
    Bioanalysis; 2015; 7(13):1561-4. PubMed ID: 26226306
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunogenicity testing strategy and bioanalytical assays for antibody-drug conjugates.
    Hoofring SA; Lopez R; Hock MB; Kaliyaperumal A; Patel SK; Swanson SJ; Chirmule N; Starcevic M
    Bioanalysis; 2013 May; 5(9):1041-55. PubMed ID: 23641695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics.
    Kaur S; Xu K; Saad OM; Dere RC; Carrasco-Triguero M
    Bioanalysis; 2013 Jan; 5(2):201-26. PubMed ID: 23330562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies.
    Ducry L; Stump B
    Bioconjug Chem; 2010 Jan; 21(1):5-13. PubMed ID: 19769391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
    Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
    Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioanalysis of antibody-drug conjugates.
    Gorovits B
    Bioanalysis; 2015; 7(13):1559-60. PubMed ID: 26226305
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality.
    Hock MB; Thudium KE; Carrasco-Triguero M; Schwabe NF
    AAPS J; 2015 Jan; 17(1):35-43. PubMed ID: 25380723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic engineering of monoclonal antibody carbohydrates for antibody-drug conjugation.
    Okeley NM; Toki BE; Zhang X; Jeffrey SC; Burke PJ; Alley SC; Senter PD
    Bioconjug Chem; 2013 Oct; 24(10):1650-5. PubMed ID: 24050213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-drug conjugates for the treatment of cancer.
    Flygare JA; Pillow TH; Aristoff P
    Chem Biol Drug Des; 2013 Jan; 81(1):113-21. PubMed ID: 23253133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate.
    Hamblett KJ; Senter PD; Chace DF; Sun MM; Lenox J; Cerveny CG; Kissler KM; Bernhardt SX; Kopcha AK; Zabinski RF; Meyer DL; Francisco JA
    Clin Cancer Res; 2004 Oct; 10(20):7063-70. PubMed ID: 15501986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A personal perspective of the development and validation of a phase-specific antibody-drug conjugate cytotoxicity potency assay.
    Wilson R
    Bioanalysis; 2013 May; 5(9):1083-97. PubMed ID: 23641698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioanalytical approaches for characterizing catabolism of antibody-drug conjugates.
    Saad OM; Shen BQ; Xu K; Khojasteh SC; Girish S; Kaur S
    Bioanalysis; 2015; 7(13):1583-604. PubMed ID: 26226309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The selection of system of detection for multiplex dot-immune analysis of antibodies].
    Poltavchenko AG; Ersh AV; Krupnitskaya YA
    Klin Lab Diagn; 2016 Apr; 61(4):229-33. PubMed ID: 30586243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conjugation, immunoreactivity, and immunogenicity of calix[4]arenes; model study to potential calix[4]arene-based Ac3+ chelators.
    Grote Gansey MH; de Haan AS; Bos ES; Verboom W; Reinhoudt DN
    Bioconjug Chem; 1999; 10(4):613-23. PubMed ID: 10411459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunogenicity of therapeutic antibodies].
    Stas P; Lasters I
    Med Sci (Paris); 2009 Dec; 25(12):1070-7. PubMed ID: 20035681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphorothyoate oligodeoxynucleotides block nonspecific binding of Cy5 conjugates to monocytes.
    Jahrsdörfer B; Blackwell SE; Weiner GJ
    J Immunol Methods; 2005 Feb; 297(1-2):259-63. PubMed ID: 15777948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selecting an optimal antibody for antibody-drug conjugate therapy: internalization and intracellular localization.
    Harper J; Mao S; Strout P; Kamal A
    Methods Mol Biol; 2013; 1045():41-9. PubMed ID: 23913140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorescent cocaine probes: a tool for the selection and engineering of therapeutic antibodies.
    Meijler MM; Kaufmann GF; Qi L; Mee JM; Coyle AR; Moss JA; Wirsching P; Matsushita M; Janda KD
    J Am Chem Soc; 2005 Mar; 127(8):2477-84. PubMed ID: 15725002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.